top of page

News

Articles Icon.jpg

Press Releases

February 13, 2025 - Ceres Nanosciences Appoints Michael Kazinski-Höfer as Board Advisor to Bolster Commercialization of Ceres’ Innovative Sample Preparation Products MANASSAS, Virginia – February 13, 2025 – Ceres Nanosciences (Ceres) is pleased to announce the appointment of Michael Kazinksi-Hofer as a Board Advisor. Michael brings a wealth of expertise in developing and commercializing sample preparation products for microbiome and liquid biopsy applications. Mr. Kazinksi is currently Vice President and General Manager of Ritter GmbH, part of Avantor. Prior to this role, he spent more than 10 years at QIAGEN, where he led and executed the vision for the sample preparation portfolio with responsibilities that included consumables, automation, customization, software and applications development, together with global performance of the business. He also served as a co-chair of the PreAnalytiX joint venture between QIAGEN and Becton Dickinson. “Michael’s leadership and technical insight into the nuances of sample preparation will be invaluable as we continue to develop robust solutions that address unmet clinical and research needs,” said Ross Dunlap, CEO of Ceres Nanosciences. In his new role as Board Advisor, Michael will provide strategic guidance on technology development, commercialization pathways, and market strategies for Ceres Nanosciences’ sample preparation products. “Ceres Nanosciences has an exceptional team and a suite of groundbreaking products that are truly reshaping the landscape of sample preparation,” said Michael Kazinski-Höfer. “The future is incredibly bright, and I am enthusiastic about the opportunity to contribute to the company’s continued success.” # # # ​About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® Particle technology into a range of diagnostic and research products and workflows. The Nanotrap Particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap Particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Virginia Catalyst Program. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com www.ceresnano.com

November 18, 2024 - Streck to distribute Ceres NEAT Liquid Biopsy Kit - Streck BCT worldwide LA VISTA, Neb., Nov. 18, 2024 /PRNewswire/ -- Streck is pleased to announce an expanded partnership with Ceres Nanosciences (Ceres) to distribute the Nanotrap® Extraction Advanced Technology (NEAT) Liquid Biopsy Kit – Streck BCT worldwide. The NEAT Liquid Biopsy Kit – Streck BCT is formulated to capture, concentrate and extract cfDNA from plasma samples isolated from Streck blood collection tubes. "Streck is excited to launch another innovative product from our strategic partner Ceres," said Matthew Kreifels, vice president of Sales, MarCom, and Business Development at Streck. "The NEAT Liquid Biopsy Kit creates efficiencies and results our customers will find invaluable when used in combination with Streck stabilization solutions." With liquid biopsy, cancer researchers have the power to identify critical biomarkers from a few milliliters of blood. However, these biomarkers can be in very small amounts, and when blood samples begin to degrade and release proteins and nucleic acids that can obscure the concentrations of biomarkers of interest, isolation becomes even more difficult. Combined use of Streck Cell-Free DNA BCT® and Nucleic Acid BCT™ with the NEAT Liquid Biopsy Kit ensures that samples remain the same from collection to analysis and that the cfDNA isolated from these samples for downstream analysis is high yield and high purity. "Ceres looks forward to seeing Streck's innovative customers use the NEAT Liquid Biopsy Kit and Streck blood collection tubes to push the frontiers of liquid biopsies," said Robbie Barbero, Ph.D., chief business officer at Ceres Nanosciences. Performance characteristics of Cell-Free DNA BCT have only been established on the Guardant360® CDx assay. Nucleic Acid BCT and NEAT Liquid Biopsy Kit – Streck BCT are for Research Use Only. Not for use in diagnostic procedures. Nucleic Acid BCT should only be used for research or in the development of new assays. About Streck, Inc. Established in 1971, Streck develops quality control and sample stabilization products that help clinical and research laboratories worldwide feel confident in the validity of their results. Streck products are manufactured in La Vista, Nebraska, and delivered to thousands of labs worldwide. About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap Particle technology into a range of diagnostic and research products and workflows. The Nanotrap Particle technology can improve diagnostic testing by capturing, concentrating, and preserving low-abundance analytes from biological samples. Nanotrap Particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Virginia Catalyst Program. Learn more, including how Ceres is partnering with leading life science, biopharmaceutical, and diagnostic companies, at www.ceresnano.com. Streck Press Contact: Matthew Kreifels Vice President of Sales, MarCom and Business Development, Streck mkreifels@streck.com Ceres Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com www.ceresnano.com SOURCE Streck

​October 24, 2024 - Ceres Nanosciences Launches Nanotrap Protein Enrichment Affinity Kits MANASSAS, Virginia – October 24, 2024 – Today, Ceres Nanosciences (Ceres) announced the launch of the Nanotrap® Protein Enrichment Affinity Kit (PEAK), a new product that uses the Nanotrap hydrogel particle technology to capture and concentrate low abundance, low molecular weight proteins and peptides while simultaneously excluding higher molecular weight proteins. This product launch coincides with a talk at the Biomarkers US 2024 conference, titled “Leveraging ultra-deep proteomes to facilitate network-informed biomarker discovery for precision medicine,” in which a Director of Global Proteomics at a pharmaceutical company presents results demonstrating that the Nanotrap PEAK significantly increases the depth of proteome profiling in plasma and cerebrospinal fluid.​​​ Nanotrap Protein Enrichment Affinity Kits have three different Nanotrap® Protein Particle chemistries offering unique protein binding profiles. They can be used individually or in combination to enhance the detection of low-abundance proteins and peptides from plasma samples, all with a simple 30-minute enrichment step prior to protein digestion. Each Nanotrap Protein Enrichment Affinity Kit is compatible with serum, plasma, cerebrospinal fluid, or urine samples and integrates seamlessly with a wide range of downstream protein digestion methods. “We understand that researchers need robust protein enrichment tools that deliver deep proteome insights without adding complexity to their workflows,” said Ben Lepene, Chief Technology Officer at Ceres Nanosciences. “That is why we’re thrilled to introduce the Nanotrap Protein Enrichment Affinity Kits, which are simple, versatile, and seamlessly fit into any proteomics pipeline.” Additional product information, including protocols and application notes are available at www.ceresnano.com/nanotrap-peak. ### ​​ ​About Ceres Nanosciences, Inc. ​ ​Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Virginia Catalyst Program. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com www.ceresnano.com

​February 28, 2024 - Introducing Ginkgo's Technology Network oday we’re thrilled to announce the creation of the Ginkgo Technology Network — a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs. ​ The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets Based on strong initial customer feedback, Ginkgo expects to add new partners to the network over time, expanding this integrated offering and helping eliminate the siloing and switching costs that limit R&D progress today ​ For over 15 years, Ginkgo has invested in building and integrating horizontal platform technologies to serve a diverse set of customer programs and needs with efficient and powerful services. Beyond Ginkgo’s homegrown capabilities, Ginkgo has acquired over a dozen companies and has deep strategic partnerships with many others in the broader biotechnology ecosystem. As such, Ginkgo is uniquely experienced as a systems integrator, offering customers a robust set of services within a unified R&D experience. Ginkgo is excited to expand this integrated capability set to include a diverse network of technology partners, providing customers access to a much more extensive suite of cutting edge technologies — all powered and enhanced by Ginkgo’s flexible automation and data, and integrated into comprehensive programs. “It’s time to eliminate the difficult – and importantly, false – choices our customers face when they are deciding how to grow new products with biology. With the Ginkgo Technology Network, our customers don’t have to wrestle on their own with the integration of different vendors or, worse, prematurely choose an approach for biological designs or analysis. Our customers give us some of their toughest problems to solve, and we have seen that unbiased and integrated R&D approaches coupled with experimentation at scale is the most powerful approach for biological engineering. Our customers are creating groundbreaking — and in many cases lifesaving products — and they deserve the best tools available to drive success in those programs. We’re proud to put the full force of our automated Foundry behind the technologies that our network partners are bringing to the table.” JASON KELLY, CEO AND CO-FOUNDER OF GINKGO BIOWORKS ​ One of the core focus areas for the Technology Network today is AI. As more companies seek to leverage the latest tools in generative AI, having an integrated approach to R&D and building robust feedback loops into computational models has become a critical differentiator, helping to determine project success. Integrating partner models and AI capabilities with Ginkgo’s automation stack can help network partners build more robust models that benefit from additional training data and reinforcement learning. Ginkgo is excited to bring this closed-loop capability to network partners and to current and future customers. ​ “Perhaps one of the most unique capabilities that Ginkgo has developed over the years is the ability to integrate many diverse computational and experimental technologies to deliver on complex customer needs at the bleeding edge of innovation across many product classes. There are no silver bullets yet in biological design and making progress will require collaboration. I believe strongly in connecting AI with physical experimentation and so I am excited about the breadth of partners we are bringing on across these areas. It’s clear that even the best AI models benefit tremendously from access to relevant labeled data and it’s equally clear that experimental designs are dramatically improved with input from AI. I’m grateful to our inaugural network partners for taking this journey with us. The opportunities in biology are too great and the challenges too complex for us to take this journey alone.” ANNA MARIE WAGNER, SVP, HEAD OF AI AND HEAD OF CORPORATE DEVELOPMENT, AT GINKGO BIOWORKS Ginkgo’s inaugural cohort of technology network partners includes, in alphabetical order: 310.AI is accelerating scientific discovery by giving scientists access to state-of-the art AI via a user-friendly chat interface. 310’s platform, 310 CoPilot ties together proprietary AI, industry-standard models, databases, visualizations, and analytics all in one user-friendly chat interface. This enables customers across industries (biotech, pharmaceutical, cosmetics, etc.) to design novel molecules and bring higher performing solutions to market faster. Advanced Medicine Partners delivers what patients deserve and what regulators expect, providing process development, manufacturing, analytical development and testing for advanced medicines, specializing in viral vectors for gene and cell therapies. AMP’s proprietary AAV manufacturing process minimizes impurities and generates industry-leading functional full capsid ratios. AMP brings extensive operational experience and has manufactured 350+ non-GMP batches and supplied 20+ preclinical studies, including IND-enabling efficacy and GLP toxicology. GMP capacity is expected to be available in Q1 2025. Avecris has developed SPRING DNA, a non-viral gene delivery system which enables next-generation genetic medicines. SPRING is a transformational platform technology that enables non-viral DNA delivery while precisely regulating gene expression in a cell-type specific way. SPRING is programmable, modular, redosable, stable and sustained. BioMap is a leading AI company dedicated to driving innovation in the life sciences sector, leveraging AI to unmask nature’s rules and generate proteins for a wide range of therapeutic and industrial applications. BioMap is a pioneer in Large Biology Language Models, having developed the world’s largest 100Bn+ parameters biology foundation model, xTrimo, trained on a vast array of multi-dimensional biological data. Combined with a proprietary fine-tuning platform, BioMap can rapidly deploy high-performance task models to support innovation across any horizontal protein design domain or modality. BioMap’s AI capabilities are supplemented with a leading team of scientists, disease experts and cutting-edge high-throughput labs. BioMap empowers its partners’s R&D ambitions by enabling them to build their own AI models with limited data and leverage BioMap’s AI Generated Protein (AIGP) Platform to design novel proteins for frontier healthcare, industry and sustainability needs. BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. The company builds translation upfront, using AI and in vivo validation to rapidly discover higher-confidence targets and precision medicines. bit.bio is a synthetic biology company focused on human cells, advancing medicine and enabling curative treatments. bit.bio’s opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency. The ioCells™ research cell product portfolio is opening up new possibilities in research and drug discovery. CATENABIO was spun out of the Doudna and Francis laboratories at UC Berkeley to enable multiple payloads on a single antibody along with flexibility of several conjugation sites per antibody. Coupled with superior stability, this creates a targeted combination approach that can deliver potent efficacy with a superior toxicity profile to address significant unmet needs in the antibody drug conjugate (ADC) market. Ceres Nanosciences makes innovative products that capture and concentrate low-abundance analytes from biological samples, enabling early and accurate detection of diseases. Cradle software solution empowers biology R&D teams with generative Machine Learning models to design better proteins, faster. Through extensive benchmarking and in-house wet-lab validation, Cradle’s models learn iteratively from small datasets. Cradles models are able to handle multi property optimization and grow more powerful after every experimental round. As a result, R&D teams that use the Cradle platform need substantially less experimental rounds to meet or exceed a protein’s target product profiles. Customers gain access to the platform through a transparent subscription-based pricing model and retain full IP of generated proteins. Cube Biotech provides a comprehensive range of products and services that address the full spectrum of protein research, from expression and purification to characterization and stabilization. Culture Biosciences utilizes innovative cloud-connected bioreactors and data science capabilities driving the digital transformation of biomanufacturing. Culture’s real-time data analysis and data-driven modeling capabilities enable clients to accelerate their biomanufacturing screening and optimization work. Evolve helps researchers working in antibodies, CARs, bi/multi-specifics, and ADCs who want to quickly incorporate AI to address discovery and engineering challenges. Fabric Nano is a biotechnology company developing a way to transform industrial chemical processes using cell-free biomanufacturing. Its advanced, flexible and easily-scalable platform produces highly stable and performant biocatalysts to enable profitable production of sustainable and bio-based chemicals. FORM BIO provides award-winning software and AI solutions for cell and gene therapy leaders. By combining data, technology and expertise, Form’s solutions accelerate timelines from discovery to clinic by providing drug developers with rapid in silico characterization, prediction, simulation and optimization of their therapeutics—enabling higher yields, enhanced safety and shorter, less expensive development cycles. With cross-disciplinary expertise spanning software engineering, biology, bioinformatics and data science, the Form Bio team collaborates closely with customers on their most pressing and strategic challenges and opportunities. JumpCode uses its proprietary CRISPRclean® technology to remove unwanted sequences, allowing researchers worldwide to extract greater insights. The company combines CRISPR-based technology and next-generation sequencing (NGS) to search for novel signals, increase sensitivity, and allow access to a range of sample types to broaden the understanding of human biology in fields from research to clinical applications including infectious disease and oncology. LEVERAGEN is a Boston-based biotech company developing next-generation humanized mouse models for antibody discovery and therapeutic biologics. Leveragen’s flagship innovation, the Singularity Sapiens mouse, marks significant progress in the development of single-domain antibodies (sdAbs), also known as nanobodies. The compact size and modular structure of sdAbs make them exceptionally versatile for constructing a broad range of biologics, including multispecific and multivalent antibodies, antibody drug conjugates, as well as key components for mRNA and cell therapies. Mana is a drug delivery platform, leveraging AI/ML-based tools to design lipid nanoparticles (LNPs) for delivery of genetic medicines including DNA and RNA-based therapeutics and vaccines. MEDIPHAGE has developed a proprietary and scalable manufacturing process using E.coli to produce ministring DNAᵀᴹ (msDNAᵀᴹ), a high-fidelity linear covalently closed (LCC) DNA vector. msDNAᵀᴹ can be used across a broad range of gene therapy modalities, including redosable non-viral gene therapy, in vivo and ex vivo gene editing, DNA vaccines, and as a starting material for the manufacturing of high fidelity viral vectors (rAAV, lentiviral) and mRNA. Medium Biosciences has a mission to build the fastest and most accurate models of biology to cure all diseases, better understand nature and create lasting abundance. Its software platform uses custom AI models to help customers create novel, better biomolecules by simulating their biophysical properties and identifying the most promising ones to be tested in the lab. Menten.AI is developing generative AI to design next-generation cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. It’s the first platform capable of designing potent and membrane-permeable macrocycles in a matter of days. The team has shown in vitro and in vivo validation of their platform for complex drug targets including protein-protein interfaces (PPIs) and intracellular targets. NeuImmune is a biopharmaceutical company developing innovative vaccines and biopharmaceuticals through precision glycoengineering and delivery of biologics that address important medical and public health needs. The company is committed to providing safe and more effective prophylactic and therapeutic treatments based on its novel biomanufacturing and delivery platforms. Phase Genomics develops cutting-edge tools for discovery and diagnostics in cancer and infectious disease, using their proprietary ultra-long-range genome sequencing technology. Their microbiome discovery platform enables the deepest view of complex microbial communities possible with current tools. Phase Genomics has generated the largest atlas of bacteriophage and antibiotic resistance reservoirs and is applying this information to combat microbial threats and isolate therapeutic proteins. ProteoNic Biosciences offers premium vector technology driving high level production of biologics as well as increased viral titers for cell and gene therapy applications. The technology is broadly applicable across cell lines and product classes, including complex molecules which are difficult to express by conventional technology. Application of this technology is designed to enable production of complex molecules at economically viable levels, resolve capacity constraints and reduce manufacturing costs. Applied to viral vectors, it has the capacity to resolve bottlenecks currently associated with lentiviral and AAV production. RESILIENCE is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions across biologics, vaccines, nucleic acids, cell and gene therapy to ensure the treatments of today and tomorrow can be made quickly, safely, andat-scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. is a synthetic biology startup spun out of Kobe University’s Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and gene therapy biofoundry services. Synplogen is building the world’s first predictive simulation of patient biology to empower the biopharma industry by informing the right experiments that identify and validate disease driver hidden effects. Turbine’s Simulated Cell™ is an interpretable cell simulation platform that captures patient biology better than currently available models, and is used for in silico experiments at scales impossible in physical assays. The Simulated Cells can be integrated into all steps of biopharma R&D to boost their likelihood of success, from identifying novel targets invisible to high throughput biological screening to optimally targeting existing therapies at the most responsive patients. Turbine is an AI-based platform for discovery, design, and accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. Ginkgo does not have its own product portfolio. As a platform company, Ginkgo makes customer-driven infrastructure investments and is incentivized to make its tools and capabilities available to customers. Ginkgo’s programs require the integration of both existing capabilities and new techniques and approaches, whether that means investing in a novel high throughput assay design, a new approach for editing cells, or a fine-tuned AI model to explore a vast design space more efficiently. This approach to biology allows customers to access a range of technical approaches rather than feel constrained by the status quo. ​ “I’ve never felt more excited by the set of capabilities we are able to offer our customers than I am today. There’s nothing more important to me than representing our customer’s voice and bringing them better solutions, because I’ve personally felt the pain of R&D constraints and would have loved to have had an integrated, end-to-end solution like the one we’re building. Our mission is to make biology easier to engineer, and that means continuously evolving our platform as new technologies emerge. Between the cutting-edge technologies we’ve acquired and our new Technology Network committed to changing the paradigm for biotech R&D, our customers don’t have to settle for fragmented or sub-scale solutions. I can’t wait to hear what our customers will be able to dream up with access to this Network and our full Foundry and Codebase. 15 years in, they know that we’re building a platform for them and that we’re committed to investing in the capabilities they want and need.” JENNIFER WIPF, SVP, HEAD OF COMMERCIAL – CELL ENGINEERING AT GINKGO BIOWORKS ​ ​ To learn more about becoming a Network Partner, please visit our website at http://ginkgobioworks.com/technology-network. If you are interested in working with Ginkgo and one or more of our Network Partners, please reach out to your Ginkgo representative or email technet@ginkgobioworks.com.

January 24, 2024 - Ceres Nanosciences Launches New Product for Cell-Free DNA Capture and Concentration  MANASSAS, Virginia – January 24, 2024 – Today at the Precision Medicine World Congress, Ceres Nanosciences (Ceres) announced the launch of a new product, the Nanotrap® Extraction Advanced Technology (NEAT) Liquid Biopsy Kit. ​ The NEAT Liquid Biopsy Kit uses the Nanotrap hydrogel particle technology to capture and concentrate cell-free DNA from plasma samples while simultaneously reducing genomic DNA contamination. The result is purer and more concentrated cell-free DNA that can be used in downstream analyses. ​ “The unique hydrogel nature of the Nanotrap particles enables size exclusion of larger, unwanted genomic DNA fragments and affinity capture and concentration of the more clinically relevant cell-free DNA fragments at the same time,” said Ben Lepene, Chief Technology Officer at Ceres Nanosciences. “We developed a simple and easy-to-use cell-free DNA extraction kit based on this novel approach and are very excited to see our customers use it to help improve outcomes for patients.” ​ The NEAT Liquid Biopsy Kit is compatible with multiple types of blood collection tubes. With automated and manual methods for plasma volumes from 1 mL to 4 mL, it can be seamlessly integrated into laboratory workflows. “The amount of circulating tumor DNA in fluids like blood is frequently present at very low concentrations in patient samples,” said Robbie Barbero, Ph.D., Chief Business Officer at Ceres Nanosciences. “We’re seeing, on average, at least 2-fold improvements in cfDNA concentration from plasma samples as compared to other cfDNA extraction kits, which will improve the detection of those low-abundance, actionable mutations.” ​ ​ Ceres is presenting performance data on the NEAT Liquid Biopsy Kit at the Precision Medicine World Congress this month and at the Advances in Genome Biology and Technology General Meeting next month. Additional information, including application notes and technical notes, are available at www.ceresnano.com/NEAT-Liquid-Biopsy-Kit. ​ # # # About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® Particle technology into a range of diagnostic and research products and workflows. The Nanotrap Particle technology can improve diagnostic testing by capturing, concentrating, and preserving low-abundance analytes from biological samples. Nanotrap Particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Virginia Catalyst Program. Learn more, including how Ceres is partnering with leading life science, biopharmaceutical, and diagnostic companies, at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com www.ceresnano.com ​ ​

​​October 25, 2023 - Ceres Nanosciences Establishes Five New Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative

September 12, 2023 - Ceres Nanosciences and Ginkgo Bioworks Partner to Bring Pathogen Monitoring Capabilities to Labs Around the World MANASSAS, Virginia and BOSTON, Massachusetts — Sept. 12, 2023 – Ceres Nanosciences, a global leader in developing wastewater testing methods based on its Nanotrap® technology, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they are partnering to bring pathogen monitoring capabilities to laboratories around the world. Pathogen monitoring and analysis capabilities, including in wastewater, are designed to help public health institutions address regional biosecurity challenges. ​ Supported by the NIH RADx Initiative, Ceres developed their Nanotrap technology for robust, sensitive, and time-saving methods to detect a wide range of pathogens in wastewater samples and has deployed those methods to a network of testing sites in the United States. These sites provide wastewater testing services nationwide to deliver valuable public health data, such as information about the relative abundance of COVID-19 variant groups over time in a community’s wastewater, to the CDC’s National Wastewater Surveillance System and to state, local, and Tribal decision makers. Ceres' Nanotrap Microbiome Particles Recently, Concentric by Ginkgo, the biosecurity unit of Ginkgo Bioworks, as part of a CDC program, demonstrated in a study with partners from XPresCheck and Louisiana State University that coupling Ceres’ aircraft wastewater testing methods with Concentric’s analysis can enable early detection of variants of SARS-CoV-2. San Francisco International Airport was the first airport to announce that it will continuously monitor airplane wastewater samples as part of a CDC program operated by Concentric and XpresCheck. Under the partnership between Ceres and Concentric, labs in countries where Concentric has biosecurity programs receive on-site training and the materials needed to implement the standardized and proven wastewater testing workflow from Ceres. Labs also receive biosecurity tools and data infrastructure to leverage automation, data analysis, bioinformatics capabilities, and other critical genomic sequencing technologies. Together, Ceres and Concentric have set up labs in the Middle East and Africa through this collaboration, offering a cutting-edge approach to biosurveillance technologies and capacity building for labs around the world that are part of Concentric’s global pathogen monitoring network. “Under our NIH RADx Initiative, we demonstrated that we can quickly stand up improved wastewater testing capabilities for labs that are experts or novices in the space,” said Robbie Barbero, Chief Business Officer at Ceres Nanosciences. “We are delighted now to be partnering with a global leader like Concentric to build a robust public health framework worldwide.” “Ceres Nanosciences has been a terrific partner in developing effective and innovative methods for identifying pathogens in wastewater,” said Matt McKnight, General Manager, Biosecurity at Ginkgo Bioworks. “By combining their laboratory expertise with our global footprint, we are building a robust global biological radar to prevent, detect, and respond to biological threats.” # # # ​ ​ About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. ​ ​ Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com ​ ​ About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGinkgo), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks), or LinkedIn. Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's biosecurity platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on August 9, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. ​ GINKGO MEDIA CONTACT: press@ginkgobioworks.com GINKGO INVESTOR CONTACT: investors@ginkgobioworks.com

January 25, 2023 - New purification system launched by Promega includes Ceres Nanosciences’ Nanotrap® particles for virus concentration

​December 1, 2022 - Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4 million award from the NIH, Ceres will identify and establish five additional centers of excellence to join the existing network of 16 sites comprising public health labs, non-profit labs, university labs, and commercial testing labs in 14 states. Ceres also will support the verification of SARS-CoV-2 genotyping from wastewater samples and the addition of this capacity to a subset of the centers of excellence. ​ coemap.png Press Release - December 1, 2022 ​ Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence ​ Each new center of excellence will receive the materials and on-site training to implement an automated Nanotrap® particle protocol, which enables same-day delivery of wastewater testing results for over 100 samples per day. Extracted nucleic acids from this automated protocol are compatible with multiple nucleic acid detection methods, including reverse transcription-quantitative polymerase chain reaction, reverse transcription-droplet digital PCR, reverse transcription digital PCR, and genomic sequencing. ​ “The United States is demonstrating global leadership in wastewater-based epidemiology through public-private partnerships like this,” said Robbie Barbero, Ph.D., Chief Business Officer at Ceres Nanosciences. “I am very proud that Ceres has once again been recognized by the U.S. government for our innovative technology and collaborative approach to advancing this field.” ​ Centers are expected to share data and results with local, state, Tribal, and Federal public health decision makers and to participate in the CDC National Wastewater Surveillance System. Each new center will be selected based on its ability to utilize the expanded testing capacity to extend services into underserved and underprivileged communities and to balance the geographic reach of the network. Interested sites can learn more and apply for the program at https://www.ceresnano.com/wastewater-coe. ​ *** ​ ​ About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com ​

October 10, 2022 - Ceres Nanosciences Launches New Nanotrap Microbiome Particles MANASSAS, Virginia — October 10, 2022 – Ceres Nanosciences (Ceres) today announced the launch of two new products, Nanotrap Microbiome B Particles and Nanotrap Enhancement Reagent 3. Labs around the world are already using Nanotrap particles to capture and concentrate microbes from samples like wastewater, saliva, and transport medium. The new products launched today will enable those customers to expand the range of microbes that can be captured and concentrated. ​ Today’s product launch occurred at WEFTEC 2022, where Ceres also released an application note demonstrating that the Nanotrap Microbiome B Particles can capture and concentrate Escherichia coli, Salmonella enterica, Campylobacter jejuni, Listeria monocytogenes, Clostridioides difficile, and crAssphage from wastewater. ​ Tomorrow, there will be a presentation describing how one of Ceres’ customers uses the Nanotrap Microbiome Particles in a single workflow to simplify wastewater monitoring for viruses, bacteria, and parasites across dozens of sites in Bangladesh. 65202-productpic.jpg Ceres' Nanotrap Microbiome Particles Nanotrap Microbiome Particles enable manual or automated methods that eliminate time consuming filtration, centrifugation, and bead-beating steps. Nanotrap Microbiome Particles are compatible with multiple sample types, nucleic acid extraction kits, and downstream analysis techniques, ensuring simple and easy integration into a laboratory’s workflow. As part of this product line expansion, the Nanotrap Magnetic Virus Particles have been renamed to Nanotrap Microbiome A Particles. “We have customers all over the world who have had great success using the Nanotrap Microbiome A Particles to capture and concentrate viruses like SARS-CoV-2, influenza, RSV, and monkeypox virus from clinical or environmental samples,” said Ben Lepene, Ceres Nanosciences CTO. “But we’ve also heard that there are some microbes that are harder to capture, and I am really excited to see what our customers can do with these new Nanotrap Microbiome B Particles.” ​ *** ​ ​ About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com ​

​​September 14, 2022 - Streck Announces Series B Investment in Ceres Nanosciences La Vista, Nebraska — September 14, 2022 – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform. ​ “Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.” This investment builds on the pre-existing partnership between Ceres and Streck, which has produced the Streck® Viral Extraction Kit, powered by Nanotrap technology, and a global distribution agreement covering Nanotrap particles for virus capture and concentration from wastewater samples. ​ “Ceres has a fantastic reputation for delivering innovative, high-quality products,” said Matthew Kreifels, Vice President of Sales. “We look forward to the positive impacts this partnership will have and working closely with their team to maximize the company’s impacts in the public health and diagnostics arenas.” ​ Streck will join Series A investor GreyBird Ventures on Ceres’ Board of Directors. ​ “We are very happy with our investment in Ceres and are pleased that Streck has joined us," said Tom Miller, GreyBird Ventures Co-Founder and Chair of Ceres’ Board. “A world-class company like Streck as a strategic partner, coupled with a Ceres team that has demonstrated the ability to solve some of the most difficult problems in health care diagnostics, is a clear catalyst for accelerated growth.” ​ ​ About Ceres Nanosciences, Inc. ​ Ceres Nanosciences is a privately held company, located in Northern Virginia, focused on incorporating its proprietary Nanotrap® particle technology into a range of diagnostic and research use products and workflows. Nanotrap® particles capture, concentrate, and preserve low abundance analytes from biological samples, enabling early and accurate detection of diseases. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, the Centers for Disease Control and Prevention, and the Commonwealth of Virginia. Ceres Nanosciences Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com ​ About Streck, Inc. ​ Established in 1971, Streck develops and manufactures products in hematology, immunology, molecular diagnostics, cell stabilization, infectious diseases, and urinalysis for clinical and research laboratories. Streck’s passion for innovation, quality and service are what makes the organization a world leader in the development of quality control and diagnostic products helping laboratories ensure accurate and timely results for patients. Streck Press Contact: ​ Matthew Kreifels Streck, Inc. 1.800.843.0912 mkreifels@streck.com ​

​​June 27, 2022 - Streck introduces viral extraction kit for clinical samples

April 6, 2022 - Ceres Nanosciences Establishes Sixteen Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative

January 10, 2022 - Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution

February 17, 2022 - Biobot Analytics and Ceres Nanosciences Announce Partnership and Establishment of Wastewater-based Epidemiology Center of Excellence

​​November 9, 2021 - Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative MANASSAS, Virginia – November 9, 2021 – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine new wastewater-based epidemiology centers of excellence, as part of the April 2021 $8.2 million award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. ​ Wastewater-based epidemiology can help communities monitor infection dynamics for SARS-CoV-2 and can serve as an early-warning system for the virus in a population, but widespread implementation has been stymied by lack of robust, high-throughput viral concentration methods. ​ Ceres’ Nanotrap® Magnetic Virus Particles address this problem by enabling rapid viral concentration directly from raw sewage, significantly reducing the time and effort required to process wastewater samples. These particles are compatible with a wide range of RNA extraction kits and detection methods, including reverse transcription-quantitative polymerase chain reaction (RT-qPCR), reverse transcription-droplet digital PCR (RT-ddPCR), and viral genome sequencing. Wastewater testing methods powered by the Nanotrap® Particles enable wastewater-based epidemiology at multiple levels in a community, including at the building level, at the neighborhoods sewershed level, and at the wastewater treatment plant level. “Our customers have processed tens of thousands of samples from college dorms, K-12 schools, sleepaway camps, government facilities, and wastewater treatment plants,” said Ben Lepene, Chief Technology Officer at Ceres Nanosciences. “A recent study by one of our university customers showed that 85% of the individual COVID-19 cases on campus were preceded by positive wastewater results.” Each Center of Excellence was selected based on its ability to utilize the expanded capacity to extend services into underserved and underprivileged communities and to provide critical information to public health decision makers. Each site received the materials and on-site training from Ceres’ field applications team to implement an automated protocol, which increases capacity to 100 samples per day and improves turnaround times to less than eight hours. ​ “These sites encompass non-profit, university, public health, and commercial testing labs in eight states with a total population of more than 120 million people,” said Tara Jones-Roe, Vice President of Sales and Marketing for Ceres Nanosciences. “We are very proud of this amazing set of organizations and look forward to identifying additional sites.” ​ Details with contact information for each Center of Excellence are listed below. ​ ***** ​ ​ Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com If you or your organization would like to learn more about how to participate in the Centers of Excellence Program, please visit https://www.ceresnano.com/wastewater or email sales@ceresnano.com. Wastewater-based COVID-19 Surveillance Centers of Excellence ​ ​ Arizona State University in collaboration with OneWaterOneHealth (Tempe, AZ) ​ Selection as a Center of Excellence has enabled Arizona State University’s Biodesign Institute and OneWaterOneHealth to scale up operations in Tribal communities from three to six reservation locations and to increase sampling frequency from monthly to weekly/biweekly. Regular meetings are conducted with Tribal epidemiologists, healthcare professionals, and community leaders to help inform the overall public health response in those communities. A high-frequency monitoring campaign for building-level hotspot surveillance of at-risk communities will be launched soon. A number of these projects have a downstream variant sequencing component, and efforts are underway with community stakeholders to integrate wastewater-derived data into existing epidemiology dashboards or to create standalone public-facing dashboards if desired and approved by the participating communities. ​ Media contact: Sandra Leander sandra.leander@asu.edu 480-727-3396 Technical contact: Rolf Halden Rolf.Halden@asu.edu ​ CIAN Diagnostics (Frederick, MD) ​ CIAN Diagnostics is a leading provider of testing services in Maryland and the mid-Atlantic. The company provides COVID-19 testing services for state, county, and local governments, and has completed over 1.5 million tests. CIAN conducts pooled testing for Maryland K-12 school systems and mobile testing for Maryland Department of Health. Selection as a Center of Excellence will enable CIAN to offer this new testing paradigm to its key clients in Maryland and beyond. ​ To learn more, contact: Sam Mullapudi Sam@ciandx.com ​ Public Health Laboratory of East Texas (Tyler, TX) ​ As one of 120 Laboratory Response Network reference laboratories supported by the Centers for Disease Control and Prevention (CDC), the Public Health Laboratory of East Texas (PHLET) routinely tests clinical and environmental samples and reports results directly to the Texas Department of Health, the CDC, and other agencies. PHLET was the first in the region to provide SARS-CoV-2 testing for patients and has provided testing to approximately 60 health care facilities, public health departments, and first responders throughout East Texas. As a Center of Excellence, PHLET aims to provide testing of wastewater to identify areas of vulnerable and disparate populations in seven counties of east Texas through collaboration with the Northeast Texas Public Health District. To learn more, contact: Rachel Roberts French 903-877-7079 office Rachel.French@uthct.edu ​ University at Buffalo – State University of New York (Buffalo, NY) ​ The University at Buffalo – State University of New York currently runs wastewater-based surveillance for Erie County, the city of Buffalo, and the University at Buffalo North Campus. This includes underserved and vulnerable populations within the city of Buffalo as well as rural populations south of the city. As a Center of Excellence, the University at Buffalo has increased testing capacity and, in collaboration with the Erie County Department of Health, is expanding services to additional underserved communities in neighborhoods and ZIP codes most directly affected by COVID-19. Efforts are underway to expand service throughout Western NY into additional underserved urban and rural populations, including Tribal lands. ​ To learn more, contact: Cory Nealon cmnealon@buffalo.edu ​ ​ University of California Los Angeles (Los Angeles, CA) ​ As a Center of Excellence, University of California Los Angeles (UCLA) has ramped up its campus-based wastewater testing program from eight to 30 locations and, for the first time ever, has been able to offer same-day results. UCLA is also collaborating with Pangolin Health to expand wastewater-based testing to K-12 schools in Los Angeles. Researchers at UCLA are using the high-throughput method available in the Center of Excellence to establish a baseline of SARS-CoV-2 trends in the wastewater system at a local K-8 school prior to vaccine approval for the 5-11 age group. ​ To learn more, contact: Bryan Ruiz bruiz@ehs.ucla.edu ​ University of California Davis in collaboration with University of California Merced (Davis, CA) ​ University of California (UC) Davis has been monitoring wastewater for the City of Davis and the UC Davis campus using Nanotrap® Magnetic Virus Particles with RT-qPCR and RT-ddPCR detection since 2020. Starting in the summer of 2021, UC Merced and UC Davis began collaborating on a new initiative, Healthy Central Valley Together, to expand wastewater testing for public health action in California's Central Valley. The project will use wastewater-based epidemiology to increase equity in access to public health data for regions with elevated poverty, food insecurity, and COVID-19 case rates. Selection as a Center of Excellence leverages external support for the project and will support the project by increasing UC Davis and Merced's wastewater testing capacity for an additional six to eight facilities in the Central Valley, as well as to expand wastewater monitoring on the UC Davis campus. ​ To learn more contact: Junior Reyes jrureyes@ucdavis.edu ​ University of Connecticut (Storrs, CT) ​ One of the first universities in the country to begin testing its own wastewater, the University of Connecticut has been using a Nanotrap® Magnetic Virus Particle method to monitor samples from 16 sites on campus on a daily basis since 2020, as well as to provide wastewater testing for other towns, universities, military facilities, and even a sleepaway camp in New England. Inclusion in the Centers of Excellence Program is enabling the University of Connecticut to increase its sample throughput from 24 to 96 samples per day and expand capacity to serve additional communities in New England. ​ To learn more, contact: Matthew Engelhardt matthew.engelhardt@uconn.edu ​ University of Kansas (Lawrence, KS) ​ Selection as a Center of Excellence has enabled the University of Kansas (KU) to monitor the community health of Kansas, including 95 rural counties, major urban centers, and military facilities. KU wastewater-based epidemiology monitoring efforts in Kansas’ eastern gateway communities provide a community health assessment of 454,041 individuals, including 84% of the population in Wyandotte County, a historically underserved community in Kansas. KU can now provide more frequent rural county testing (moving from a three-month to every other week rotation) and is sharing the data with local authorities, including wastewater treatment operators, county health departments, and the Kansas Department of Health and Environment. ​ To learn more, contact: Brendan M. Lynch blynch@ku.edu 785-864-8855 Mindie Paget mpaget@ku.edu 785-864-0013 ​​ West Virginia University (Morgantown, WV) ​ Selection as a Center of Excellence has enabled West Virginia University (WVU) to improve turn-around time four-fold and to improve weekly max sustained sample throughput by an order of magnitude (from 72 to 720 samples per week). Many of the current and projected collection sites are embedded in traditionally underserved rural communities with minimal access to routine healthcare and the testing results will enable more equitable allocation of healthcare resources to these communities. WVU has partnered with Marshall University and the West Virginia Bureau for Public Health to regularly test samples from 60 sites in West Virginia. To learn more, contact: Tim Driscoll timothy.driscoll@mail.wvu.edu ​ ​ ***** ​ This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. The current contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, under Contract No. 75N92021C00012. ​

April 21, 2021 - Ceres Nanosciences Receives $8.2M NIH Award to Improve Wastewater-Based COVID-19 Surveillance  MANASSAS, Va. — April 21, 2021 — Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve diagnostic testing, is announcing today that it has been awarded a contract from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) Initiative for $8.2 million to support the development and implementation of wastewater-based surveillance systems for COVID-19 powered by the Nanotrap® particle technology in a network of sites with an emphasis on underserved and vulnerable populations. Wastewater surveillance can help communities monitor spatial and temporal trends in SARS-CoV-2 infection at a population level, but widespread implementation has been stymied by the lack of a sensitive, rapid, high-throughput viral concentration method. Nanotrap® Magnetic Virus Particles address this need by capturing and concentrating virus directly from raw sewage prior to RNA extraction and detection and can be readily adapted for small-scale as well as large-scale surveillance systems. Ceres will work closely with a multidisciplinary team of scientists at Emory University to develop and implement a wastewater-based COVID-19 surveillance framework in the metro-Atlanta area with a focus on use cases for underserved and vulnerable populations, such as correctional facilities, low-income neighborhoods, and long-term care facilities. “This collaboration between Ceres and Emory will generate robust evidence to support the CDC’s objective of developing a national wastewater surveillance system that meets the information needs of city, county, and state decision makers to effectively respond to the COVID-19 pandemic across multiple use cases in underserved community settings,” said Christine Moe, Eugene J. Gangarosa Chair in Safe Water and Sanitation at the Rollins School of Public Health at Emory University. ​ In parallel, Ceres will be identifying and launching a network of centers of excellence for high-throughput wastewater-based COVID-19 surveillance. “Researchers from the University of California San Diego (UCSD) recently demonstrated a Nanotrap® particle high-throughput method for wastewater surveillance that can process more than 100 samples in a day with an ability to detect 1 asymptomatic infected individual in a building with 415 residents,” said Ben Lepene, CTO of Ceres Nanosciences. “We are very excited to identify additional sites around the country to implement similar approaches.” This award builds on the $6.57 million RADxSM initiative award that Ceres received in 2020 to increase the manufacturing capacity of Ceres’ Nanotrap® Magnetic Virus Particles. Nanotrap® Magnetic Virus Particles improve diagnostic testing for respiratory viruses by eliminating the need for RNA extraction kits, reducing sample processing time, and improving the sensitivity of the downstream diagnostic assays in point-of-care settings and high-throughput laboratories. This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. The current contract is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, under Contract No. 75N92021C00012. *** About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202

​February 17, 2021 - Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing  MANASSAS, Va. — February 17, 2021 — Ceres Nanosciences, a privately held company that makes innovative products to improve diagnostic testing, announced that it has completed the build-out of a new 12,000-square-foot Advanced Particle Manufacturing Plant in Innovation Park, Prince William County, Virginia. ​ The new facility will be capable of generating a supply of Ceres’ Nanotrap® Magnetic Virus Particles to enable more than 10 million COVID-19 tests per month, with room for added capacity in the future. ​ Nanotrap® Magnetic Virus Particles improve diagnostic testing for COVID-19 by eliminating the need for RNA extraction kits, reducing sample processing time, and improving the sensitivity of the downstream assays in point-of-care systems, high-throughput laboratory tests, and wastewater and pooled sample testing workflows. Nanotrap® Magnetic Virus Particles also improve diagnostic testing for influenza virus, RSV, and variants of SARS-CoV-2. The new facility was constructed in under 4 months with funding support from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. The rapid construction of the site was made possible with the support of Prince William County. The site is part of Pruitt Corporation’s Discovery Court development, and Pruitt also served as the general contractor. Facility Logix provided construction management support. ​ “This new facility is a huge step up in capacity for Ceres, giving us the ability to rapidly respond and scale to current and future virus outbreaks and testing needs,” said Ross Dunlap, Ceres Nanosciences CEO. “We are thrilled that our new manufacturing plant is also located within Innovation Park near our existing R&D facility,” said Ben Lepene, Ceres Nanosciences CTO. “This means that we can ensure a stable supply of Nanotrap® particles to our growing portfolio of customers while simultaneously maintaining our development efforts for new Nanotrap® products right down the street.” This project is supported by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative and has been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92020C00021. *** About Ceres Nanosciences, Inc. Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com. Press Contact: Ross M. Dunlap Ceres Nanosciences, Inc 1.800.615.0418 ext. 202 rdunlap@ceresnano.com

Press Releases
Sphere_Bckgrd_CMYK_Large.png
News Publications
news.jpeg

News Publications

​January 26, 2024  - New Products Posted to GenomeWeb: Ceres Nanosciences, Nonacus, Twist Bioscience Genome Web

​January 18, 2024  - Wastewater Tests Can Find Mpox, Study Finds. Expect More Bugs to Be Tracked That Way Associated Press

October 2, 2023  - Ginkgo Bioworks Seeks to Improve Pathogen Surveillance With Google Cloud Partnership Genome Web​

September 12, 2023  - Ceres Nanosciences and Ginkgo Bioworks Partner to Bring Pathogen Monitoring Capabilities to Labs Around the World biospace

June 8 2023  - Morgan State University Named a Center of Excellence in Wastewater-based Epidemiology Program Morgan State Press

​​​​​​​February 12, 2023  - State Hygienic Lab now testing Iowa wastewater for flu virus The Gazette

December 7, 2022  - Ceres Nanosciences uses fresh funding to improve cancer, superbug, wastewater testing Washington Business Journal

​December 01, 2022 - Ceres Nanosciences Wins $1.4M in NIH RADx Funding for Additional Wastewater Epidemiology Centers Genome Web

April 13, 2022 - Ceres Nanosciences establishes 6 wastewater epidemiology centers WaterWorld

February 10, 2022 - UB to expand COVID-19 wastewater surveillance in WNY UBNow

December 15, 2021 - Nanotrap particles can improve current sequencing workflows of SARS-CoV-2 News Medical Life Sciences

March 3, 2021 - Ceres Nanosciences is growing its footprint and headcount to improve Covid-19 tests. That’s just the start. Washington Business Journal

July 8, 2021 - Meet 50 players changing Greater Washington’s startup and innovation scene Washington Business Journal

June 24, 2021 - Emory University researchers awarded NIH grant to conduct COVID-19 surveillance through detection of SARS Coronavirus-2 in wastewater EMORY News Center

April 23, 2021 - RADx expands COVID-19 home and point-of-care testing, wastewater surveillance NIH

April 21, 2021 - NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance Genome Web

April 20, 2021 - Mason start-up Ceres Nanosciences experiences big wins and increases footprint in Prince William County George Mason University Press

News Form
Sphere_Bckgrd_CMYK_Large.png

We look forward to speaking with you. Please fill out the below information and a Ceres team member will be in touch with you shortly.

Sales and Product Support

Thanks for submitting your request.
We will be in touch with you shortly.

bottom of page